Julia Bonavitacola

Patients can benefit both financially and clinically by enrolling in ongoing clinical trials, said Eric Lander, MD.

The recent FDA approval of lenacapavir is encouraging in its promise of long-term HIV prevention but might not be available for the vast majority of people in the US.

The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most vulnerable, explains Colleen Kelley, MD, MPH, Rollins School of Public Health at Emory University.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across the globe, including in areas where the PURPOSE trials were conducted.

Early trials found that both garadacimab and sebetralstat were safe when used in patients living with hereditary angioedema, which speaks to the promise of the FDA-approved garadacimab.

Making clinical trials easier to find for clinicians and making protocols for entering clinical trials more lenient can help to improve access to clinical trials on a national and local level, explains Eric Lander, MD, of Minnesota Oncology.

Democratic leaders assert the Emergency Medical Treatment and Labor Act (EMTALA) remains vital for emergency care, countering confusion from recent policy changes affecting abortion rights and patient safety.

The recent approval of lenacapavir could change the way that clinicians approach both treating and preventing HIV in those at risk, as long as the treatment can get into their hands.

The FDA approval marks the first approval of a type of pre-exposure prophylaxis that would only require 2 treatments per year.

The recent approval of garadacimab can help to treat patients with hereditary angioedema (HAE) along with sebetralstat, which is awaiting FDA approval, explains Timothy Craig, DO, Penn State Health.

Early circulating tumor DNA (ctDNA) changes predict survival in mismatch repair or microsatellite instability–high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICIs).

Patients with type 2 diabetes had a lower risk of glaucoma when they used glucagon-like peptide 1 (GLP-1) receptor agonists across multiple studies.

With the approval of the FDA, garadacimab can help patients with hereditary angioedema (HAE) prevent attacks by shutting down the contact pathway.

Learning the best type of HIV prevention for those at highest risk can start with conversations about their options, writes Zandraetta Tims-Cook, MD, MPH, AAHIVS

Target trial emulation study finds no added effectiveness or persistence with combination therapy for plaque psoriasis.

The Trump administration has ended a program seeking a vaccine for HIV, the first in a series of decisions that is leaving vaccine research and expertise behind.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

The announcement of the new members of the CDC Advisory Committee on Immunization Practice comes days after the HHS secretary removed all previous members of the panel.

Both monotherapy and combination therapy containing epcoritamab had high response rates and survival benefits when compared with usual care.

Those who developed primary open-angle glaucoma (POAG) had lower mental health scores compared with those who had not developed the condition.

Specific protein signatures could predict a future diagnosis of Crohn disease and ulcerative colitis, potentially enabling earlier intervention and improving patient outcomes.

Sodium reduction is key to lowering blood pressure in adults with type 2 diabetes, a study finds.

About 40% of people living with HIV in an international survey did not make joint decisions regarding treatment with their provider despite reporting a high amount of trust.

Artificial intelligence (AI) provides a major tool in the evolution of thoracic care, as clinicians work to catch lung cancer earlier to provide better prognosis.

The PURPOSE trials illuminated the ways in which lenacapavir could be used as a means of pre-exposure prophylaxis effectively, but also featured several adverse events.

Insurance hurdles in value-based cancer care create delays and anxiety for patients and providers, complicating access to essential treatments, explained Coral Omene, MD, PhD, of Rutgers Cancer Institute and RWJBarnabas Health.

With potential lung cancer nodules sometimes slipping through the cracks, educating stakeholders about artificial intelligence (AI) that can catch nodules early could be helpful in cancer treatment.

Pentacam and corneal topography were more sensitive to tear film abnormalities when measuring the curvature of the cornea in those with dry eye.

Mild asthma could be better treated with the recent approval of the combination of albuterol/budesonide.